Neoadjuvant Combo Reduces Volume of High-Risk Prostate Tumors
Abiraterone plus prednisone combined with leuprolide decreases tumor size compared with leuprolide alone in men with high-risk prostate cancer.
PROSTATE CANCER ADVISOR
Prostate Cancer
Features
-
-
PCa Recurrence Predictors in Whole Gland Cryotherapy Identified
Older age and high-risk disease are among the factors independently associated with biochemical recurrence of prostate cancer following whole gland cryotherapy. -
Non-Standard Therapies Used in 20% of Localized High-Risk PCa Cases
Using EBRT alone or ADT alone for high-risk localized prostate cancer is associated with worse survival outcomes. -
Prostate Cancer ADT Found to Increase Depression Risk
Men who receive androgen deprivation therapy after radical prostatectomy have a nearly 2-fold increased risk of depression compared with those who receive no post-surgical treatment. -
Adjuvant Docetaxel Possibly Beneficial in High-Risk Prostate Cancer
In a study, adding docetaxel to androgen deprivation and radiation therapy for selected men with high-risk localized prostate cancer improved overall and metastasis-free survival.
Latest Prostate Cancer News
Metastatic Site Predicts Death Risk in Advanced Prostate Cancer
A recent study of men with stage IV prostate cancer revealed that liver-only metastasis is associated with worse cancer-specific and overall survival than bone-only and lung-only metastasis
Radiation Therapy May Have a Role in Oligometastatic Prostate Cancer
In a single-institution study, men with oligometastatic prostate cancer who received stereotactic ablative radiation to metastatic lesions had a 52% rate of biochemical progression-free survival at 1 year, a study found.
CVD Prior to Oral Antiandrogen Therapy for Prostate Cancer Increases Mortality Risk
In a study, men who had pre-existing cardiovascular disease prior to taking abiraterone or enzalutamide for advanced prostate cancer had a 16% to 56% increased 6-month risk.
Facility Experience Impacts Survival Time After Prostate Surgery
In a large study, men who underwent radical prostatectomy at centers that had the largest annual prostate cancer caseload lived a median 13.2 months longer than those who had the surgery at centers with the lowest caseload.
Skeletal-Related Events Common After CRPC Development
Large observational study reveals a 40% cumulative incidence rate of first skeletal-related events following development of castration-resistant prostate cancer.
Quality of Life Outcomes Comparable Regardless of Treatment With HRT or CRT for Low-Risk Prostate Cancer
Hypofractionated radiotherapy (HRT) offers quality-of-life outcomes similar to conventional radiation therapy for men with low-risk prostate cancer, according to recently published results of a phase 3 randomized study. HRT offers a less expensive and more convenient treatment option for some patients, and in light of the new findings about quality of life, should be considered…
Prostate Cancer At Biopsy Linked to Low Natural Killer Cells
In a study, natural killer cell activity (NKA) below 200 pg/mL predicted a nearly 5-fold greater risk of having a positive prostate biopsy compared with higher NKA values.
Study Supports Ultra-Hypofractionated Radiotherapy for Prostate Cancer
Ultra-hypofractionated and conventionally fractionated radiotherapy for intermediate- or high-risk prostate cancer are associated with similar 5-year failure-free survival rates, a randomized phase 3 trial found.
Adjuvant Radiotherapy Cuts Prostate Cancer Recurrence Risk
Adjuvant radiotherapy following radical prostatectomy (RP) for PCa with positive margins or extracapsular extension prolongs biochemical recurrence-free survival compared with RP alone, a study found.
FDA Clears Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer
In the phase 3 ARAMIS trial, darolutamide, a nonsteroidal androgen receptor inhibitor, significantly delayed development of metastasis in men with nonmetastatic castration-resistant prostate cancer.
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
